Americana Partners LLC Has $1.05 Million Holdings in Stryker Corporation $SYK

Americana Partners LLC lessened its stake in Stryker Corporation (NYSE:SYK) by 39.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,982 shares of the medical technology company’s stock after selling 1,950 shares during the quarter. Americana Partners LLC’s holdings in Stryker were worth $1,048,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at about $27,000. CGC Financial Services LLC acquired a new position in Stryker in the fourth quarter valued at about $29,000. Strive Asset Management LLC acquired a new position in Stryker in the third quarter valued at about $30,000. ANTIPODES PARTNERS Ltd acquired a new position in Stryker in the third quarter valued at about $34,000. Finally, Copia Wealth Management raised its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Performance

Stryker stock opened at $316.39 on Monday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $325.22 and its two-hundred day moving average price is $349.76. The stock has a market cap of $121.29 billion, a PE ratio of 36.62, a P/E/G ratio of 1.99 and a beta of 0.80.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

A number of research firms recently commented on SYK. Canaccord Genuity Group dropped their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Truist Financial reiterated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Finally, Leerink Partners assumed coverage on Stryker in a research report on Monday, April 13th. They issued an “outperform” rating and a $410.00 target price on the stock. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.